Notes
2015 US dollars
equivalent to $45 000 Australian dollars
Reference
Bohensky MA, et al. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia. Value in Health 19: 1009-1015, No. 8, Dec 2016. Available from: URL: http://doi.org/10.1016/j.jval.2016.05.013
Rights and permissions
About this article
Cite this article
Nivolumab cost effective for BRAF-advanced melanoma. PharmacoEcon Outcomes News 769, 21 (2017). https://doi.org/10.1007/s40274-017-3657-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3657-9